EMAIL THIS PAGE TO A FRIEND

Toxicology letters

In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.


PMID 25448279

Abstract

In the present study, we evaluated the inhibitory potentials of finasteride for the major human hepatic UDP-glucuronosyltransferases (UGTs) (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B7, and UGT2B15) in vitro using LC-MS/MS by specific marker reactions in human liver microsomes (except for UGT2B15) or recombinant supersomes (UGT2B15). Of the seven tested UGTs, finasteride potently, selectively, and competitively inhibited UGT1A4-mediated trifluoperazine-N-glucuronidation in human liver microsomes with an IC₅₀ value of 11.5 ± 1.78 μM and Ki value of 6.03 ± 0.291 μM. This inhibitory potency was similar to that of hecogenin, a well-known inhibitor of UGT1A4. However, finasteride did not seem to inhibit any of the other six UGTs: UGT1A1, UGT1A3, UGT1A6, UGT1A9, UGT2B7, or UGT2B15. Similarly, finasteride markedly inhibited UGT1A4 activity in recombinant human UGT1A4 supersomes, with a Ki value of 6.05 ± 0.410 μM. In addition, finasteride strongly inhibited UGT1A4-catalyzed imipramine-N-β-D-glucuronidation. However, on the basis of an in vitro-in vivo extrapolation, our data strongly suggested that finasteride is unlikely to cause clinically significant drug-drug interactions mediated via inhibition of the hepatic UGT enzymes involved in drug metabolism in vivo.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

31097
1-Naphthol, PESTANAL®, analytical standard
C10H8O
M1381
4-Methylumbelliferone, ≥98%
C10H8O3
C9377
Chenodeoxycholic acid, ≥97%
C24H40O4
C1050000
Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard
C24H40O4
C1290 Chlorpropamide, analytical standard, ≥97%
C10H13ClN2O3S
PHR1284 Chlorpropamide, Pharmaceutical Secondary Standard; Certified Reference Material
C10H13ClN2O3S
C1905000 Chlorpropamide, European Pharmacopoeia (EP) Reference Standard
C10H13ClN2O3S
SML0536
Efavirenz, ≥98% (HPLC)
C14H9ClF3NO2
F1293
Finasteride, ≥98% (HPLC), powder
C23H36N2O2
34202
Finasteride, VETRANAL, analytical standard
C23H36N2O2
Y0000090
Finasteride, European Pharmacopoeia (EP) Reference Standard
C23H36N2O2
Y0001604
Finasteride for peak identification, European Pharmacopoeia (EP) Reference Standard
C23H36N2O2
Y0000011
Hymecromone, European Pharmacopoeia (EP) Reference Standard
C10H8O3
N0630
Niflumic acid
C13H9F3N2O2
Y0000824
Niflumic acid, European Pharmacopoeia (EP) Reference Standard
C13H9F3N2O2
PHR1023
Theophylline, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8N4O2
1653004
Theophylline, certified reference material, United States Pharmacopeia (USP) Reference Standard
C7H8N4O2
T0800000
Theophylline, European Pharmacopoeia (EP) Reference Standard
C7H8N4O2
PHR1151
Theophylline melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
C7H8N4O2
T8516
Trifluoperazine dihydrochloride, ≥99%, powder
C21H24F3N3S · 2HCl
T6062
Trifluoperazine hydrochloride, meets USP testing specifications
C21H24F3N3S · 2HCl
1685000
Trifluoperazine hydrochloride, United States Pharmacopeia (USP) Reference Standard
C21H24F3N3S · 2HCl
T2000000
Trifluoperazine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C21H24F3N3S · 2HCl
PHR1292
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
C10H13N5O4
Z1900000
Zidovudine, European Pharmacopoeia (EP) Reference Standard
C10H13N5O4
1724500
Zidovudine, United States Pharmacopeia (USP) Reference Standard
C10H13N5O4